PMID- 34959326
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 13
IP  - 12
DP  - 2021 Nov 30
TI  - Polymeric Nanoparticles Properties and Brain Delivery.
LID - 10.3390/pharmaceutics13122045 [doi]
LID - 2045
AB  - Safe and reliable entry to the brain is essential for successful diagnosis and 
      treatment of diseases, but it still poses major challenges. As a result, many 
      therapeutic approaches to treating disorders associated with the central nervous 
      system (CNS) still only show limited success. Nano-sized systems are being 
      explored as drug carriers and show great improvements in the delivery of many 
      therapeutics. The systemic delivery of nanoparticles (NPs) or nanocarriers (NCs) 
      to the brain involves reaching the neurovascular unit (NVU), being transported 
      across the blood-brain barrier, (BBB) and accumulating in the brain. Each of 
      these steps can benefit from specifically controlled properties of NPs. Here, we 
      discuss how brain delivery by NPs can benefit from careful design of the NP 
      properties. Properties such as size, charge, shape, and ligand functionalization 
      are commonly addressed in the literature; however, properties such as ligand 
      density, linker length, avidity, protein corona, and stiffness are insufficiently 
      discussed. This is unfortunate since they present great value against multiple 
      barriers encountered by the NPs before reaching the brain, particularly the BBB. 
      We further highlight important examples utilizing targeting ligands and how 
      functionalization parameters, e.g., ligand density and ligand properties, can 
      affect the success of the nano-based delivery system.
FAU - Ribovski, Lais
AU  - Ribovski L
AUID- ORCID: 0000-0001-8886-8020
AD  - Department of Molecules and Materials, MESA+ Institute for Nanotechnology and 
      TechMed Institute for Health and Biomedical Technologies, Faculty of Science and 
      Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The 
      Netherlands.
FAU - Hamelmann, Naomi M
AU  - Hamelmann NM
AUID- ORCID: 0000-0002-7126-4818
AD  - Department of Molecules and Materials, MESA+ Institute for Nanotechnology and 
      TechMed Institute for Health and Biomedical Technologies, Faculty of Science and 
      Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The 
      Netherlands.
FAU - Paulusse, Jos M J
AU  - Paulusse JMJ
AUID- ORCID: 0000-0003-0697-7202
AD  - Department of Molecules and Materials, MESA+ Institute for Nanotechnology and 
      TechMed Institute for Health and Biomedical Technologies, Faculty of Science and 
      Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The 
      Netherlands.
LA  - eng
GR  - n.a./Health Holland/
GR  - n.a./Dutch Ministry of Economic Affairs/
GR  - EURO-NANOMED2017-178/EuroNanoMed III/
PT  - Journal Article
PT  - Review
DEP - 20211130
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC8705716
OTO - NOTNLM
OT  - blood-brain barrier
OT  - brain delivery
OT  - controlled drug delivery
OT  - nanomedicine
OT  - nanoparticles
OT  - polymers
OT  - therapeutics
COIS- The authors declare no conflict of interest.
EDAT- 2021/12/29 06:00
MHDA- 2021/12/29 06:01
PMCR- 2021/11/30
CRDT- 2021/12/28 01:03
PHST- 2021/10/25 00:00 [received]
PHST- 2021/11/22 00:00 [revised]
PHST- 2021/11/26 00:00 [accepted]
PHST- 2021/12/28 01:03 [entrez]
PHST- 2021/12/29 06:00 [pubmed]
PHST- 2021/12/29 06:01 [medline]
PHST- 2021/11/30 00:00 [pmc-release]
AID - pharmaceutics13122045 [pii]
AID - pharmaceutics-13-02045 [pii]
AID - 10.3390/pharmaceutics13122045 [doi]
PST - epublish
SO  - Pharmaceutics. 2021 Nov 30;13(12):2045. doi: 10.3390/pharmaceutics13122045.